Coherus Oncology

CompanyUnited StatesFounded 2010

RORWikidata

Coherus Oncology develops 8 assets, the furthest approved (Cimerli in diabetic macular edema). Mostly antibody acting on IL27, CCR8 and PDCD1; based in the United States, founded in 2010.

8
Assets
Furthest stage
Approved
Raised
$119M
13
Trials
14
Signals

Pipeline

8
  • Cimerli

    Neutralizes VEGF-A to inhibit abnormal blood vessel growth and vascular leakage.

    Approved, Antibody, diabetic macular edema, diabetic retinopathy

  • toripalimab

    Blocks PD-1 to restore T-cell immune responses against cancer cells.

    Approved, Antibody, PDCD1, nasopharyngeal carcinoma, esophageal squamous cell carcinoma

  • Yusimry

    Neutralizes TNF to reduce inflammatory signaling.

    Approved, Antibody, Active Rheumatoid Arthritis, ankylosing spondylitis

5 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

1

In the full profile

  • Evidence behind the mechanisms5
  • Trials22
  • Funding rounds and grants4
  • Deals20
  • People24
  • Signals17
  • Similar companies6

Intelligence